Dealmaking

KKR countersues DOJ, FTC, arguing ‘classic case study of government agency overreach’

The KKR complaint says: 'Now, on the eve of a leadership transition, the Antitrust Division has threatened a final act of agency overreach: the imposition of draconian and grossly disproportionate penalties on KKR based on alleged premerger paperwork errors that were immaterial to antitrust clearance.'

Tailwater co-founder on energy investment under Trump; New Mountain Capital’s double healthcare deals

New Mountain backs two health tech firms.

What makes a good candidate for a single-asset continuation fund?

Rob Campbell, head of North America at ICG's Strategic Equity unit, outlines elements for a successful CV when just one asset is involved and why such deals differ from co-investments.

Tailwater's Jason Downie: Immense power resources needed for new data center rollout

'You can’t get there without natural gas power generation.'

DTCP’s Zahl Limbuwala: UK AI plans ‘encouraging’ for PE; Ambienta cautious on data center sustainability

“Private equity has been a key investor into the development of new data center capacity for years,' says Limbuwala.

'Managers are starting to get cracking,' says Cambridge Associates’ Andrea Auerbach in a 2025 Outlook Q&A; deal announcements pick up

Palm Peak acquires Pacific Shoring Products.

Venture debt: Key lessons learned

In part 16 of his series on venture debt, Zack Ellison from Applied Real Intelligence reflects on key investment lessons he has learned.

Cambridge Associates' Andrea Auerbach: 'After 10 long quarters, we are back in positive territory for buyouts'

'There are half a trillion dollars in distributions that should have happened by now. LPs have been reminding GPs of this fact for a while, increasing pressure for more exits in 2025.'

MidEuropa preps Diagnostyka for IPO; EV tariffs create opportunities for PE in semiconductors

Diagnostyka is a Polish diagnostics services provider.

Energy Capital Partners inks $26.6bn sale; Audax, EQT, NMS Capital pursue clinical trial deals; Last call for Deal of the Year nominations

ECP agrees to sell Calpine Corp to energy company Constellation for $26.6 billion.